Menu
Back to Journals » OncoTargets and Therapy » Volume 5
Treating metastatic soft-tissue or bone sarcomas – potential role of ridaforolimus
Authors Keedy V
Received 10 January 2012
Accepted for publication 19 January 2012
Published 22 August 2012 Volume 2012:5 Pages 153—160
DOI https://doi.org/10.2147/OTT.S19055
Review by Single anonymous peer review
Peer reviewer comments 2
Vicki L Keedy
Vanderbilt University Medical Center, Nashville, TN, USA
Abstract: Sarcomas of soft tissue and bone are a rare group of cancers hallmarked by relative insensitivity to cytotoxic chemotherapy. The development of targeted therapies in the treatment of sarcoma has been difficult due to the significant heterogeneity and rarity of these diseases. Inhibition of the mammalian target of rapamycin (mTOR) has emerged as an exciting treatment approach and is being studied extensively in sarcoma patients. Ridaforolimus is a second generation mTOR inhibitor that has shown potential benefit in the treatment of sarcoma. Recently a Phase III study demonstrated an improvement in progression-free survival when patients with at least stable disease after treatment with standard chemotherapy received maintenance ridaforolimus compared to placebo. The results of this study show that mTOR is an important pathway in soft tissue and bone sarcomas and represents an exciting opportunity for the improvement in the treatment of our patients.
Keywords: sarcoma, mTOR, ridaforolimus
© 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.